Innate Pharma (IPH)
Euronext
Key stats Fiscal year 2024
Income statement
- Revenue
- 20,121,000 -67.4%
- Net income
- -49,471,000
- Operating income
- -51,575,000
- Earnings per share
- -0.61
- R&D expense
- 51,980,000
Growth and profitability
- Operating margin
- -256.32
- Net margin
- -245.87
- Return on equity
- -560.01
- Return on assets
- -44.54
- Free cash flow margin
- -36.22
Balance sheet
- Total assets
- 111,059,000
- Shareholders' equity
- 8,834,000
- Cash and equivalents
- 66,396,000
- Current ratio
- 2.60
Cash flow and ratios
- Operating cash flow
- -6,896,000
- Free cash flow
- -7,287,000
Fiscal year end: · Source: ESEF · filings.xbrl.org
Innate Pharma trades on Euronext under the ticker symbol IPH. This page brings together its price chart, company profile, key financial figures and technical indicators.